GRFS - Grifols SA Debt to Book Capitalization Ratio

Graphic logo of Grifols SA (GRFS)

Serving as the primary valuation tool, this chart on GURU.Markets illustrates the price action of Grifols, S.A. (GRFS), where management has transitioned to hired professionals to reduce debt, and the indicator stands at 1.50. The business is expanding its influence in the biologics sector through the acquisition of plasma centers and scientific partnerships. Meanwhile, Grifols, S.A. (GRFS) maintains internal control over plasma fractionation while outsourcing logistics.

GRFS (Grifols Biemat) Debt to Book Value history from 07/04/2022 to 10/28/2026
Core merchandise of Grifols SA

This metric decouples the fundamental stability of Grifols, S.A. (GRFS) from market volatility by measuring the share of total liabilities within the equity structure to assess financial leverage. By analyzing this leverage chart—debt to book capitalization—investors can monitor management reorganization risks, while a successful recovery in plasma collection margins confirms the company's ability to maintain its debt load within safe limits.

Who Grifols, S.A. competes with

Debts to Book Capitalization ARGX (argenx SE)|biontech.de - Debts to Book Capitalization|Debt to Book Capitalization Ratio ABIVAX (ABVX)|ADMA: Debt to Net Assets Ratio|PTGX (Protagonist Therapeutics Inc) - Debt to Book Capitalization Ratio|Immunovant Therapeutics (IMVT) - Debt to Book Value|KNSA (Kiniksa Pharmaceuticals) - Debts to Book Capitalization|Debts to Book Capitalization adaptivebiotech.com (ADPT)|Celldex Therapeutics, Inc. (CLDX) - Debt to Book Value|Debt to Net Assets Ratio Aurinia Pharmaceuticals Inc (AUPH)|Debts to Book Capitalization BCRX|Vera Corp - Debts to Net Assets|DNTH: Debt to Book Capitalization Ratio|PHVS: Debt to Book Value|ABCL (AbCellera Corp) - Debt to Book Capitalization Ratio|Debt to Book Value Tourmaline Bio Inc|PGEN (Intrexon) - Debt to Book Value|Debts to Book Capitalization PHAR|Debt to Book Capitalization Ratio Nektar Therapeutics NKTR|Debt to Book Value Ratio upstreambio.com (UPB)|ZBIO: Debts to Book Capitalization|Debts to Book Value Immunome Inc IMNM|Debts to Book Capitalization GOSS|KALV: Debt to Net Assets|Debt to Book Capitalization Ratio Septerna Inc SEPN|pieris.com (PVLA) - Debt to Net Assets Ratio|SVRA: Debts to Book Capitalization|Debts to Net Assets Rigel Pharma|ANAB - Debts to Book Capitalization|Debts to Book Capitalization Ratio ATXS (Astria Corp)|ENGN: Debt to Book Capitalization Ratio|RAPT Therapeutics Inc. - Debts to Book Value|JBIO - Debt to Book Capitalization Ratio|ACRS: Debt to Book Capitalization Ratio|Kyverna - Debt to Book Capitalization Ratio|Debts to Net Assets Tiziana Life Sciences, Ltd.|CABA - Debt to Book Value|Debt to Net Assets Ratio VTYX|THTX (Theratechnologies) - Debt to Book Capitalization Ratio|Debts to Net Assets Avalo Therapeutics, Inc. AVTX|Debt to Book Value ELDN|Debts to Net Assets Agenus, Inc AGEN|Climb Bio Inc - Debts to Book Capitalization|Zura Bio Ltd (ZURA) - Debts to Book Capitalization|aTyr Pharma - Debt to Book Value|Adagene Inc. (ADAG) - Debts to Net Assets|ImageneBio - Debts to Book Capitalization|Debt to Net Assets STTK|Equillium, Inc. (EQ) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio connectbiopharm.com (CNTB)|Immunic (IMUX) - Debts to Book Capitalization|Atara Biotherapeutics, Inc. - Debts to Book Capitalization Ratio|Debt to Book Capitalization Ratio IFRX (InflaRx GmbH)|XFOR: Debts to Net Assets|Debt to Book Capitalization Ratio adicetbio.com (ACET)|Celularity (CELU) - Debts to Book Capitalization Ratio|INMB - Debts to Book Capitalization|Debt to Net Assets Ratio Barinthus Biotherapeutics PLC|Debts to Book Capitalization KZR|Debts to Book Capitalization SABS (SAB Biotherapeutics Inc)|Debt to Book Capitalization Ratio Akari Therapeutics|Enlivex Therapeutics Ltd - Debt to Net Assets Ratio|QTTB: Debt to Book Capitalization Ratio|GOVX - Debt to Book Value|EDSA: Debts to Book Capitalization|Debts to Book Capitalization iBio Corporation|CARM - Debt to Book Value|Debt to Net Assets Ratio xtlbio.com|BOLT (Bolt Biotherapeutics) - Debts to Book Capitalization|Debts to Net Assets HCWB (hcwbiologics.com)|Aptevo Therapeutics Inc. - Debt to Book Capitalization Ratio|AIM ImmunoTech, Inc. - Debt to Book Value|ADTX: Debt to Book Capitalization Ratio|gribio.com (GRI) - Debt to Book Value|XRTX: Debt to Book Value|HIND (Vyome Holdings Inc.) - Debts to Book Capitalization|Debt to Book Capitalization Ratio Revelation Bio (REVB)|Debt to Book Value Ratio Indaptus Corp|Scinai Immunotherapeutics - Debts to Book Capitalization|Debts to Book Value calcimedica.com (CALI)|AFMD (Affimed N.V.) - Debts to Book Capitalization|Allakos Inc - Debt to Net Assets|Debt to Book Capitalization Ratio HOOKIPA (HOOK)|IGMS - Debt to Net Assets Ratio|iTeos Therapeutics - Debts to Book Capitalization|oceanbiomedical.com (OCEA) - Debts to Net Assets|Debts to Book Capitalization TC BioPharm TCBP|Debts to Book Capitalization Ratio THRD